help button home button Biophys. J.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pogozheva, I. D.
Right arrow Articles by Mosberg, H. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pogozheva, I. D.
Right arrow Articles by Mosberg, H. I.

Biophys J, August 1998, p. 612-634, Vol. 75, No. 2

Opioid Receptor Three-Dimensional Structures from Distance Geometry Calculations with Hydrogen Bonding Constraints

Irina D. Pogozheva, Andrei L. Lomize, and Henry I. Mosberg

College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109 USA

Three-dimensional structures of the transmembrane, seven alpha -helical domains and extracellular loops of delta , µ, and kappa  opioid receptors, were calculated using the distance geometry algorithm, with hydrogen bonding constraints based on the previously developed general model of the transmembrane alpha -bundle for rhodopsin-like G-protein coupled receptors (Biophys. J. 1997. 70:1963). Each calculated opioid receptor structure has an extensive network of interhelical hydrogen bonds and a ligand-binding crevice that is partially covered by a beta -hairpin formed by the second extracellular loop. The binding cavities consist of an inner "conserved region" composed of 18 residues that are identical in delta , µ, and kappa  opioid receptors, and a peripheral "variable region," composed of 19 residues that are different in delta , µ, and kappa  subtypes and are responsible for the subtype specificity of various ligands. Sixteen delta -, µ-, or kappa -selective, conformationally constrained peptide and nonpeptide opioid agonists and antagonists and affinity labels were fit into the binding pockets of the opioid receptors. All ligands considered have a similar spatial arrangement in the receptors, with the tyramine moiety of alkaloids or Tyr1 of opioid peptides interacting with conserved residues in the bottom of the pocket and the tyramine N+ and OH groups forming ionic interactions or H-bonds with a conserved aspartate from helix III and a conserved histidine from helix VI, respectively. The central, conformationally constrained fragments of the opioids (the disulfide-bridged cycles of the peptides and various ring structures in the nonpeptide ligands) are oriented approximately perpendicular to the tyramine and directed toward the extracellular surface. The results obtained are qualitatively consistent with ligand affinities, cross-linking studies, and mutagenesis data.

Biophys J, August 1998, p. 612-634, Vol. 75, No. 2
© 1998 by the Biophysical Society   0006-3495/98/08/612/23  $2.00


This article has been cited by other articles:


Home page
 Protein Eng Des SelHome page
D. Ott, Y. Neldner, R. Cebe, I. Dodevski, and A. Pluckthun
Engineering and functional immobilization of opioid receptors
Protein Eng. Des. Sel., March 1, 2005; 18(3): 153 - 160.
[Abstract] [Full Text] [PDF]

Home page
 Protein Sci.Home page
M. Aburi and P. E. Smith
Modeling and simulation of the human {delta} opioid receptor
Protein Sci., August 1, 2004; 13(8): 1997 - 2008.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
D. Townsend IV, P. S. Portoghese, and D. R. Brown
Characterization of Specific Opioid Binding Sites in Neural Membranes from the Myenteric Plexus of Porcine Small Intestine
J. Pharmacol. Exp. Ther., January 1, 2004; 308(1): 385 - 393.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
J. Pil and J. Tytgat
Serine 329 of the {micro}-Opioid Receptor Interacts Differently with Agonists
J. Pharmacol. Exp. Ther., March 1, 2003; 304(3): 924 - 930.
[Abstract] [Full Text] [PDF]

Home page
 Biophys. JHome page
M. G. Paterlini
Structure Modeling of the Chemokine Receptor CCR5: Implications for Ligand Binding and Selectivity
Biophys. J., December 1, 2002; 83(6): 3012 - 3031.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
I. J. McFadyen, H. Houshyar, L.-Y. Liu-Chen, J. H. Woods, and J. R. Traynor
The Steroid 17alpha -Acetoxy-6-dimethylaminomethyl-21-fluoro-3-ethoxy-pregna-3,5-dien-20-one (SC17599) Is a Selective {micro}-Opioid Agonist: Implications for the {micro}-Opioid Pharmacophore
Mol. Pharmacol., October 1, 2000; 58(4): 669 - 676.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
C. Ulens, M. Van Boven, P. Daenens, and J. Tytgat
Interaction of p-Fluorofentanyl on Cloned Human Opioid Receptors and Exploration of the Role of Trp-318 and His-319 in {micro}-Opioid Receptor Selectivity
J. Pharmacol. Exp. Ther., September 1, 2000; 294(3): 1024 - 1033.
[Abstract] [Full Text]

Home page
 Protein Eng Des SelHome page
C. M. Topham, L. Mouledous, and J.-C. Meunier
On the spatial disposition of the fifth transmembrane helix and the structural integrity of the transmembrane binding site in the opioid and ORL1 G protein-coupled receptor family
Protein Eng. Des. Sel., July 1, 2000; 13(7): 477 - 490.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
L. Mouledous, C. M. Topham, C. Moisand, C. Mollereau, and J.-C. Meunier
Functional Inactivation of the Nociceptin Receptor by Alanine Substitution of Glutamine 286 at the C Terminus of Transmembrane Segment VI: Evidence from a Site-Directed Mutagenesis Study of the ORL1 Receptor Transmembrane-Binding Domain
Mol. Pharmacol., March 1, 2000; 57(3): 495 - 502.
[Abstract] [Full Text]

Home page
 Protein Eng Des SelHome page
M. Filizola, L. Laakkonen, and G. H. loew
3D modeling, ligand binding and activation studies of the cloned mouse {delta}, {micro} and {kappa} opioid receptors
Protein Eng. Des. Sel., November 1, 1999; 12(11): 927 - 942.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
S. M. Wade, W. K. Lim, K.-L. Lan, D. A. Chung, M. Nanamori, and R. R. Neubig
Gi Activator Region of alpha 2A-Adrenergic Receptors: Distinct Basic Residues Mediate Gi versus Gs Activation
Mol. Pharmacol., November 1, 1999; 56(5): 1005 - 1013.
[Abstract] [Full Text]

Home page
 J. Biol. Chem.Home page
G. Mace, C. Blanpied, L. J. Emorine, P. Druet, and G. Dietrich
Morphine-like Activity of Natural Human IgG Autoantibodies Is because of Binding to the First and Third Extracellular Loops of the {micro}-Opioid Receptor
J. Biol. Chem., July 16, 1999; 274(29): 20079 - 20082.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
K. Befort, C. Zilliox, D. Filliol, S. Yue, and B. L. Kieffer
Constitutive Activation of the delta  Opioid Receptor by Mutations in Transmembrane Domains III and VII
J. Biol. Chem., June 25, 1999; 274(26): 18574 - 18581.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
C. Mollereau, L. Mouledous, S. Lapalu, G. Cambois, C. Moisand, J.-L. Butour, and J.-C. Meunier
Distinct Mechanisms for Activation of the Opioid Receptor-Like 1 and kappa -Opioid Receptors by Nociceptin and Dynorphin A
Mol. Pharmacol., February 1, 1999; 55(2): 324 - 331.
[Abstract] [Full Text]

Home page
 J. Biol. Chem.Home page
F. Meng, Q. Wei, M. T. Hoversten, L. P. Taylor, and H. Akil
Switching Agonist/Antagonist Properties of Opiate Alkaloids at the delta Opioid Receptor Using Mutations Based on the Structure of the Orphanin FQ Receptor
J. Biol. Chem., July 14, 2000; 275(29): 21939 - 21945.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the Biophysical Society.